Coherus BioSciences (CHRS) Stock Forecast & Price Target

$1.24

-0.08 (-6.06%)

(As of 09/6/2024 ET)

Coherus BioSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Coherus BioSciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 2 have given a hold rating, and 4 have given a buy rating for CHRS.

Consensus Price Target

$6.92
457.80% Upside

High Forecast	$12.00
Average Forecast	$6.92
Low Forecast	$1.50

According to the 6 analysts' twelve-month price targets for Coherus BioSciences, the average price target is $6.92. The highest price target for CHRS is $12.00, while the lowest price target for CHRS is $1.50. The average price target represents a forecasted upside of 457.80% from the current price of $1.24.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.92	$8.00	$8.83	$14.63
Forecasted Upside	457.80% Upside	252.60% Upside	206.91% Upside	159.12% Upside

Get Coherus BioSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Ad Weiss Ratings

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coherus BioSciences Stock vs. The Competition

Type	Coherus BioSciences	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	457.80% Upside	1,206.56% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/16/2024	UBS Group 4 of 5 stars	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$4.00 ➝ $1.50	-3.23%
8/5/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00	+788.88%
7/1/2024	Robert W. Baird 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$9.00 ➝ $8.00	+362.43%
5/13/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$8.00 ➝ $7.00	+258.97%
11/8/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
10/23/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$8.00 ➝ $7.00	+112.12%
Get the Latest News and Ratings for CHRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.
10/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$7.00 ➝ $6.00	+59.57%
7/24/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$12.00	+179.72%
3/14/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$21.00 ➝ $23.00	+261.07%
11/14/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$13.00 ➝ $11.00	+41.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:28 PM ET.

CHRS Forecast - Frequently Asked Questions

What is Coherus BioSciences' forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus BioSciences is $6.92, with a high forecast of $12.00 and a low forecast of $1.50.
Should I buy or sell Coherus BioSciences stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares.
Does Coherus BioSciences's stock price have much upside?: According to analysts, Coherus BioSciences's stock has a predicted upside of 223.48% based on their 12-month stock forecasts.
Has Coherus BioSciences been downgraded by Wall Street analysts recently?: Over the previous 90 days, Coherus BioSciences's stock had 1 downgrade by analysts.
What analysts cover Coherus BioSciences?: Coherus BioSciences has been rated by research analysts at HC Wainwright, Robert W. Baird, and UBS Group in the past 90 days.
Do Wall Street analysts like Coherus BioSciences more than its competitors?: Analysts like Coherus BioSciences less than other "medical" companies. The consensus rating score for Coherus BioSciences is 2.67 while the average consensus rating score for "medical" companies is 2.77. Learn more on how CHRS compares to other companies.